Log In
BCIQ
Print this Print this
 

Monalizumab (NN8765-3658) (formerly IPH2201)

Also known as: Anti-NKG2a (formerly IPH 2201, IPH22XX)

  Manage Alerts
Collapse Summary General Information
Company Novo Nordisk A/S
DescriptionAntibody targeting killer cell lectin-like receptor subfamily C member 1 (KLRC1; CD159a; NKG2A)
Molecular Target Killer cell lectin-like receptor subfamily C member 1 (KLRC1) (CD159a) (NKG2A)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$1,312.7M

$252.7M

$1,052.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/24/2015

$1,275.0M

$250.0M

$1,025.0M

02/10/2014

$37.7M

$2.7M

$27.0M

Get a free BioCentury trial today